Aschoff wrote, “Intellipharmaceutics reported revenue of $1.1 million and EPS of $(0.07) for its FY3Q14 (ended August), in line with our estimates. Total revenue exclusively came from licensing revenue from Par for a full quarter of commercial sales of 15 and 30mg generic Focalin XR. The 180-day first-filer exclusivity for the 15mg strength expired on May 19, and Intellipharmaceutics estimates that it maintained about 40% and 25% market share of the total prescriptions dispensed for the 15 and 30 mg strengths, respectively. We look forward to additional generic drug approvals (expecting approvals of generic Glucophage XR, Effexor XR, and Protonix to come next). Intellipharmaceutics has current cash of $3.3 million. In August 2014, Intellipharmaceutics introduced its branded PODRAS platform that can prevent drug overdose. The company expects to begin clinical trials in Canada and the US in the coming months to further evaluate Rexista incorporating its PODRAS platform, subject to the availability of funds.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of 12.2% and a 54.9% success rate. Aschoff has a -40.3% average return when recommending IPCI, and is ranked #169 out of 3335 analysts.